DR. KEVIN E. JULIAN, M.D.

INDIANAPOLIS, IN

Research Active
Orthopaedic Surgery NPI registered 21+ years 50 publications 2014 – 2026 NPI: 1992700488
SARS-CoV-2COVID-19PrognosisInternship and ResidencyCurriculumAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsSurveys and QuestionnairesEducation, Medical, GraduateRecurrenceInternal MedicineMultiple MyelomaAntibodies, BispecificRemission InductionB-Cell Maturation Antigen

Practice Location

1550 E COUNTY LINE RD
INDIANAPOLIS, IN 46227-0990

Phone: (317) 497-6497

What does KEVIN JULIAN research?

Dr. Julian studies multiple myeloma, a type of blood cancer, as well as acute myeloid leukemia (AML). He investigates the effectiveness of various therapeutic agents, including elranatamab and teclistamab, for patients who have not responded well to traditional treatments. His research also looks into the safety and outcomes for specific groups, such as elderly patients, those with kidney issues, and patients who have previously undergone other therapies. Additionally, he examines the psychological impacts of childhood abuse on college students, showcasing how early life experiences can affect health in later life.

Key findings

  • In a multicenter analysis of 130 patients with multiple myeloma treated with elranatamab, 65% responded to the drug, and 36% achieved complete remission, although the median survival was 14.6 months with complications in 38% of patients.
  • In one case study, elranatamab combined with CAR-T therapy resulted in full recovery for a patient with central nervous system-involved multiple myeloma, showing no signs of disease eight months post-treatment.
  • In a study of 134 newly diagnosed AML patients treated with venetoclax, 65% showed a positive response with an average survival of 381 days, despite some experiencing serious side effects initially.
  • For patients with relapsed/refractory multiple myeloma and prior BCMA therapy, the response rate to teclistamab was 49%, compared to 62% for those without prior treatment, highlighting the impact of previous therapies on outcomes.
  • In a study of 680 patients with hip abductor tendon tears, those treated with suture anchors had an average improvement of 32.5 points on the Harris Hip Score, compared to 21.9 points for those treated with transosseous sutures.

Frequently asked questions

Does Dr. Julian study multiple myeloma?
Yes, Dr. Julian's research primarily focuses on multiple myeloma and explores treatments like elranatamab and teclistamab.
What treatments has Dr. Julian researched?
He has researched multiple treatments, including elranatamab for multiple myeloma and venetoclax for acute myeloid leukemia.
Is Dr. Julian's work relevant to elderly patients?
Yes, he has examined the effectiveness of treatments for older patients with multiple myeloma, showing similar treatment responses across age groups.
What conditions does Dr. Julian address in children?
He explores the genetic impacts of child abuse on health, focusing on how early experiences affect later psychological and physical well-being.
How does Dr. Julian's research help patients with leukemia?
His studies provide insights into effective treatment regimens and outcomes for patients with newly diagnosed acute myeloid leukemia.

Publications in plain English

The WONE Index as a Multidimensional Assessment of Stress Resilience: A Development and Validation Study.

2026

Journal of medical Internet research

Roos LG, Gilliland D, Julian K, Misra R

Plain English
Researchers created and tested a new tool called the WONE Index to better understand how stress and resilience interact in full-time workers. They studied over 1,300 adults and found that the Index effectively divides stress into three areas (work stress, personal stress, and burnout) and resilience into seven categories, such as emotion regulation and social connections. This tool can help identify specific stressors and coping resources, making it useful for tailoring mental health support in workplaces and health programs. Who this helps: This helps employees and employers by improving mental health resources at work.

PubMed

Epigenetic Responses to Abusive versus Accidental Injuries in Children: A Cross-sectional Epigenome Wide Association Meta-analysis.

2026

medRxiv : the preprint server for health sciences

Campbell KA, Raut A, Julian K, Kaczor K, Makoroff K +2 more

Plain English
This study examined how child abuse and accidental injuries affect children at a genetic level by analyzing DNA changes in saliva samples from 175 children with different types of injuries. The researchers found that abuse was linked to changes in DNA methylation at 11 specific sites that are important for brain function and immune response. This is significant because it shows that early experiences of abuse may not only impact immediate physical health but also have long-term effects on a child's overall biological health. Who this helps: This research benefits healthcare providers and child welfare professionals working to understand and address the impacts of child abuse on health.

PubMed

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

2026

American journal of hematology

Jones MK, Sanchez J, Connor M, Julian K, Rezac R +14 more

Plain English
This research looked at how well patients with newly diagnosed acute myeloid leukemia (AML) do when treated with a standard drug combination, using a full 28 days of a drug called venetoclax. Out of 134 patients studied, 65% responded well to the treatment, and the average survival time was about 381 days. Although some patients experienced serious blood-related side effects early on, these side effects lessened in later cycles without causing more infections or needing more blood transfusions. Who this helps: This benefits patients with newly diagnosed AML and their doctors by providing insights into an effective treatment regimen.

PubMed

Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions.

2026

EJHaem

Julian K, Peterson B, Mohyuddin GR

Plain English
This study looked at a patient with multiple myeloma involving the central nervous system, which is usually hard to treat. After other treatments failed, a drug called Elranatamab worked remarkably well, leading to full recovery and independence for the patient. Eight months after further treatment, the patient showed no signs of disease, highlighting the potential of Elranatamab combined with CAR-T therapy in tackling challenging cases of myeloma. Who this helps: This benefits patients with difficult-to-treat multiple myeloma and their doctors.

PubMed

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

2026

Blood cancer journal

Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C +37 more

Plain English
This study looked at how well the drug elranatamab works for patients with multiple myeloma who have had little success with other treatments. Researchers analyzed data from 130 patients treated at nine U.S. centers and found that 65% of them responded to the drug, with 36% achieving complete remission. However, the duration of benefits was shorter than in other trials, with patients living a median of 14.6 months after starting treatment, and complications like infections were common in 38% of patients. Who this helps: This research benefits patients with multiple myeloma and their doctors by providing insight into the effectiveness and challenges of using elranatamab in real-world settings.

PubMed

Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation.

2026

Blood neoplasia

Davis JA, McElwee J, Gonzalez R, Julian K, Nachar VR +18 more

PubMed

INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS.

2025

Retinal cases & brief reports

Alcibahy Y, Julian K, Bonilla MF, Mohamed A, Amrani S +1 more

Plain English
This study focused on treating a 27-year-old man with an eye condition caused by tuberculosis, which was leading to complications like bleeding in the eye. The patient received a treatment called faricimab, which helped reduce inflammation in his eyes significantly within just one week after treatment. This matters because it shows that faricimab can be an effective additional option for managing serious eye issues related to tuberculosis, potentially improving patient outcomes. Who this helps: This helps patients with tuberculosis-related eye diseases.

PubMed

Shame, guilt, and drinking motives as mediators between child maltreatment and problematic alcohol use in college students.

2025

Journal of American college health : J of ACH

Julian K, Allbaugh LJ

Plain English
This study examined how feelings of shame and guilt affect drinking habits among college students who experienced maltreatment in childhood. It found that higher levels of shame and guilt led to increased drinking, particularly to cope with negative emotions or to improve mood. Specifically, childhood maltreatment was linked to worse alcohol use outcomes through these feelings and motives, indicating a need for targeted support for affected students. Who this helps: This information is valuable for college students who have experienced childhood maltreatment and for the counselors and support services that assist them.

PubMed

Clinical Outcomes of Hip Abductor Repair Using Transosseous Sutures Versus Suture Anchors: A Systematic Review and Meta-analysis.

2025

Orthopaedic journal of sports medicine

Portela-Parra E, Sappey-Marinier E, Julian K, Bini SA

Plain English
This study looked at two surgical techniques for repairing tears in the hip abductor tendon, which can cause pain in the hip area. Researchers reviewed 21 studies involving 680 patients and found that people who had repairs using suture anchors (SA) reported a greater improvement in hip function, with an average increase of 32.5 points on the Harris Hip Score compared to 21.9 points for those treated with transosseous sutures (TS). However, the suture anchor group also showed a higher rate of re-tearing at 6.7% compared to 1.3% for the transosseous group, suggesting careful consideration is needed when choosing a repair method. Who this helps: This research benefits patients with hip abductor tendon tears and their surgeons by providing information on different repair methods.

PubMed

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.

2025

Blood cancer journal

Davis JA, Snyder J, Rice M, Moore DC, Cahoon C +12 more

PubMed

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

2025

Blood advances

Dima D, Afrough A, Goel U, Grajales-Cruz AF, Khouri J +39 more

Plain English
This study looked at how effective and safe a drug called teclistamab is for patients with multiple myeloma who also have kidney problems. Out of 384 patients, 21% had renal impairment, and they experienced similar rates of serious side effects and treatment responses compared to those without kidney issues, with 52% of the patients with renal impairment responding to treatment. Importantly, most patients' kidney function didn’t worsen after starting treatment, which means teclistamab can be a viable option for these patients. Who this helps: This benefits patients with multiple myeloma who have kidney impairment, including those on dialysis.

PubMed

Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia.

2025

Research and practice in thrombosis and haemostasis

Everhardt T, Julian K, Benefield R, Wilson A, Wilson N +3 more

Plain English
This study examined how a medication called dexamethasone affects patients with a rare blood disorder called immune thrombocytopenia (ITP), focusing on differences between obese and nonobese patients. Researchers found that 93% of nonobese patients had a positive response to the treatment, while only 71% of obese patients did, and the complete response rate was 68% for nonobese patients compared to 48% for obese patients. This is important because it shows that obese patients may not respond as well to a common treatment, indicating a need for better treatment strategies for this group. Who this helps: Patients with immune thrombocytopenia, particularly those who are obese.

PubMed

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

2025

Blood cancer journal

Pasvolsky O, Dima D, Feng L, Dong W, Richards T +46 more

Plain English
This study looked at how well the cancer treatment teclistamab works for older patients with relapsed refractory multiple myeloma, specifically those aged 75 and older. Researchers analyzed data from 385 patients and found that 22% were in the older group. They discovered that older patients had fewer severe disease characteristics, with 44.6% having high-risk genetic factors compared to 57.9% in younger patients, but the effectiveness of teclistamab was similar across ages, with an overall response rate of 62% for older patients and 53% for younger patients. Who this helps: This research benefits elderly patients with multiple myeloma who are considering treatment options.

PubMed

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

2025

Blood cancer journal

Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A +39 more

Plain English
This study looked at the effectiveness and safety of a treatment called teclistamab for patients with multiple myeloma who had already received other BCMA-targeted therapies. Out of 385 patients, those with previous BCMA therapy had a lower chance of responding to teclistamab (49% response rate) compared to those without prior treatment (62% response rate), and their cancer lasted longer without worsening (4.6 months versus 8.2 months). Importantly, patients who waited more than 8.7 months after their last BCMA treatment before starting teclistamab had better results, with a median progression-free survival of 8.1 months. Who this helps: Patients with relapsed or refractory multiple myeloma who have previously used BCMA-targeted treatments.

PubMed

Rhodococcus equi Endocarditis in Prosthetic Valve of a Heart Transplant Recipient.

2025

JACC. Case reports

Guru S, Ali O, Jaafar N, Sharma R, Guru N +1 more

Plain English
This study focused on a 57-year-old man who had a heart transplant and developed an infection caused by Rhodococcus equi, a type of bacteria. The patient experienced severe symptoms, including cough, diarrhea, and weight loss, and tests revealed that his prosthetic heart valve was infected. The research highlights that Rhodococcus equi can lead to serious heart infections in people with weakened immune systems, and finding the right treatment, including antibiotics and managing immune suppression, is essential for recovery. Who this helps: This information helps doctors treating heart transplant patients and those with weakened immune systems.

PubMed

The past, present, and future of myeloma staging and risk prognostication.

2025

The oncologist

Baysal M, Julian K, Sborov D, Godara A, McClune B +3 more

Plain English
This study looked at how methods for determining the severity and risk of myeloma (a type of blood cancer) have changed over time. Researchers evaluated the older and current systems used for staging myeloma and identified improvements needed for future developments to make predictions about patient outcomes more accurate. This work is important because better staging can lead to more effective treatment plans and potentially improve survival rates for patients. Who this helps: Patients and their doctors.

PubMed

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

2025

Blood cancer journal

Afrough A, Dima D, Razzo B, Goel U, Sannareddy A +41 more

Plain English
This study looked at how the presence of soft tissue tumors (specifically, plasmacytomas) affects treatment outcomes for patients with multiple myeloma being treated with a drug called teclistamab. Researchers examined 385 patients and found that 28% had a more severe type called true extramedullary disease (EMD), which led to poorer outcomes: only 38% responded to treatment, and they had a median survival of just 9.5 months. In contrast, those without soft tissue tumors had a much better response rate of 62.4% and survival that had not yet been reached. Who this helps: This research helps doctors improve treatment plans for multiple myeloma patients with soft tissue plasmacytomas.

PubMed

Multiple Myeloma in Young Patients: A Scoping Review.

2024

Clinical lymphoma, myeloma & leukemia

Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K +5 more

Plain English
This study looked at younger patients with multiple myeloma, a type of blood cancer, and found that there is not enough clear data on their specific needs and outcomes. The researchers reviewed 201 studies, identifying that younger patients (under 50 years old) may have better treatment tolerance but also need more dedicated research to address their unique challenges. It matters because understanding these younger patients better can lead to improved care and treatment options tailored to them. Who this helps: This helps younger patients facing multiple myeloma and their healthcare providers.

PubMed

Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias.

2024

Leukemia & lymphoma

Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S +7 more

PubMed

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.

2024

Blood cancer journal

Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C +12 more

PubMed

Stem Cells and Congenital Heart Disease: The Future Potential Clinical Therapy Beyond Current Treatment.

2023

Current cardiology reviews

Julian K, Garg N, Hibino N, Jain R

Plain English
This study looks at congenital heart disease (CHD), which is the most common heart issue in newborns and often requires surgery for severe cases. Researchers are exploring the use of stem cells as a new way to treat CHD, especially for a specific condition called hypoplastic left heart syndrome. Early findings show promise for using stem cells to improve treatments, which could lead to better outcomes for patients who currently face high risks of complications or death. Who this helps: This helps patients with congenital heart disease and their families, as well as doctors seeking new treatment options.

PubMed

Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.

2023

The British journal of ophthalmology

Pleyer U, Al-Mutairi S, Murphy CC, Hamam R, Hammad S +6 more

Plain English
This study looked at how well the drug adalimumab works for adults with active non-infectious intermediate, posterior, or panuveitis (NIIPPU), a condition affecting the eye. Out of 149 patients, 91% achieved a state where their disease was inactive at least once during the study, and the number of patients completely off corticosteroids increased from 35% to 52% over the year. These findings show that adalimumab not only helps control the disease but also improves quality of life and reduces healthcare costs for these patients. Who this helps: This helps patients with active non-infectious intermediate, posterior, or panuveitis.

PubMed

Disparities in Treatment of Closed Distal Radius Fractures in Patients Aged 18-64 Years and ≥65 Years by Insurance Type.

2023

The Journal of hand surgery

Tankersley MP, Zhuang T, Julian K, Fernandez A, Kamal RN +1 more

Plain English
This study looked at how insurance type affects the treatment of wrist fractures in people aged 18-64 and those 65 and older. It found that older adults with Medicaid were less likely to have surgery quickly (12.1% within 21 days) compared to those with Medicare (15.9%) or commercial insurance (17.5%). Among younger patients, those with Medicaid had a lower surgery rate (16.2%) than those with commercial insurance (21.1%) and were more likely to have complications, like poor healing after surgery. Who this helps: This research helps younger patients with Medicaid insurance who suffer wrist fractures.

PubMed

Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials.

2023

Leukemia & lymphoma

Bindal P, Najjar M, Koehn K, Godara A, Sborov DW +4 more

PubMed

Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.

2023

Transplantation and cellular therapy

Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO +3 more

Plain English
This study looked at using stored CD34+ stem cells to help patients with relapsed refractory multiple myeloma (RRMM) recover from low blood cell counts after receiving CAR T-cell therapy. Out of 19 patients who received the stem cell boost, 95% had successful recovery of their blood cell production, with neutrophils returning to normal in about 14 days, and they did not need growth factors or blood transfusions afterward. This approach appears safe and effective, addressing a significant challenge these patients face after treatment. Who this helps: This helps patients with relapsed multiple myeloma who experience prolonged low blood cell counts after CAR T-cell therapy.

PubMed

Light Therapy for Adolescent Depression: A Scoping Review.

2023

Current psychiatry reports

Ballard R, Parkhurst J, Julian K, Pasetes LN, Fawcett A +3 more

Plain English
This research looks at how bright light therapy (BLT) might help treat depression in teenagers. It found that while BLT has been safe with few side effects for adults, there aren’t enough solid studies on its effectiveness for young people. More research is necessary to confirm if BLT can effectively help teenagers with depression. Who this helps: This helps teenagers struggling with depression and their doctors.

PubMed

Thoracic splenosis: an important consideration in oncology patients.

2023

BMJ case reports

Julian K, Vasekar M

Plain English
This study looked at a condition called splenosis, where splenic tissue grows in different parts of the body after an injury to the spleen or after its removal. Researchers found that while splenosis is often harmless and doesn't cause symptoms, it can sometimes appear like cancer on medical scans, leading to confusion in patients with existing tumors. Recognizing splenosis in these cases is crucial to prevent unnecessary surgeries and to manage patient care correctly. Who this helps: This helps patients with a history of spleen injuries or removal, particularly those undergoing cancer treatment.

PubMed

A review of cardiac autonomics: from pathophysiology to therapy.

2022

Future cardiology

Julian K, Prichard B, Raco J, Jain R, Jain R

Plain English
This study looked at how the heart's nerve connections affect its function and how understanding this can lead to better treatments for heart diseases. The research emphasized the importance of both the heart's internal nerve system and external factors that influence heart activity, highlighting that more therapies are needed for serious conditions like severe heart failure and persistent irregular heartbeats. Improving our knowledge of these nerve systems could be crucial for creating new treatments. Who this helps: This benefits patients with heart conditions, particularly those who have severe heart failure or arrhythmias.

PubMed

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.

2022

Therapeutic advances in hematology

Steinbach M, Julian K, McClune B, Sborov DW

Plain English
This research paper looks at new treatment options for patients with multiple myeloma, a type of blood cancer. It finds that while these new therapies can be very effective, they also come with specific side effects that need to be managed carefully to keep patients safe and improve treatment outcomes. Understanding these effects and providing the right support can help doctors use these innovative treatments more effectively. Who this helps: This helps patients with multiple myeloma and their healthcare providers.

PubMed

Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.

2022

Future cardiology

Mausteller KG, Eisele CD, Julian K, Patel P, Bansal A +2 more

Plain English
This research looked at how well direct oral anticoagulants (DOACs) work for people with obesity, who often face higher health risks. The studies reviewed showed that DOACs like apixaban, rivaroxaban, edoxaban, and dabigatran are generally safe and effective for obese patients, similar to their use in patients of normal weight. This is important because it means that doctors have reliable treatment options for preventing blood clots in obese individuals. Who this helps: Patients with obesity who need blood thinning treatments.

PubMed

Navigating Kidney Transplantation in the Early Phase of Coronavirus Disease 2019: Screening Patients With Reverse Transcriptase Polymerase Chain Reaction and Low-Radiation-Dose Chest Computed Tomography.

2021

Transplantation proceedings

Butt FK, Julian K, Kadry Z, Jain A

Plain English
This study focused on how to safely conduct kidney transplants during the COVID-19 pandemic. Researchers developed a testing protocol that included a quick COVID-19 test followed by a low-radiation chest scan for all transplant patients and living donors. They successfully performed 17 kidney transplants (8 from living donors and 9 from deceased donors) without any infections, showing that they could safely increase the number of transplants during a challenging time. Who this helps: This helps patients awaiting kidney transplants and medical teams involved in transplantation efforts.

PubMed

Imagist Poetry and Clinical Medicine: Arts of Observation, Precision, and Expression.

2021

Academic medicine : journal of the Association of American Medical Colleges

Soni A, Kaur G, Razeghi S, Ouyang A, Stoute J +4 more

PubMed

Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.

2021

BMJ case reports

Julian K, Bucher D, Jain R

Plain English
This study looked at a 65-year-old man who experienced breathing problems and nausea after getting COVID-19. He had serious blood clots and a low blood platelet count, which led to a diagnosis of heparin-induced thrombocytopenia (HIT) without ever having received heparin. This discovery of HIT occurring due to COVID-19 is important because it shows how the virus can lead to rare but serious complications in patients. Who this helps: This information benefits doctors and healthcare providers who care for COVID-19 patients.

PubMed

Out-of-Pocket Costs of Insulin and Diabetes-Related Supplies Among Patients With Type 1 Diabetes.

2021

Clinical therapeutics

Julian K, Ba DM, Liu G, Leslie DL, Chuang CH

Plain English
This study looked at how much money patients with type 1 diabetes have to pay out of their own pockets for insulin and related supplies between 2005 and 2017. Researchers found that the average annual cost for these patients increased significantly, making it harder for them to afford the necessary treatment. These findings highlight the urgent need for laws to limit the rising prices of insulin, which can greatly affect patients' health and finances. Who this helps: This helps patients with type 1 diabetes and their families.

PubMed

Utility of Ct values in differentiating COVID-19 reinfection versus prolonged viral shedding in an immunocompromised patient.

2021

BMJ case reports

Julian K, Shah N, Banjade R, Bhatt D

Plain English
This study looked at a 26-year-old man with cancer who tested positive for COVID-19 twice: once before chemotherapy and again just after starting treatment. The researchers focused on understanding how to tell if a patient is reinfected with COVID-19 or just still shedding the virus from a previous infection, using a specific lab measure called Ct values. They highlighted the importance of this distinction to avoid confusion in the care of immunocompromised patients. Who this helps: This benefits doctors treating immunocompromised patients who may have confusing COVID-19 test results.

PubMed

The effect of pulsed xenon ultraviolet light disinfection on healthcare-associated Clostridioides difficile rates in a tertiary care hospital.

2020

American journal of infection control

Attia F, Whitener C, Mincemoyer S, Houck J, Julian K

Plain English
This study looked at whether using special UV light to clean hospital rooms could reduce the rates of Clostridioides difficile infections (CDI), which are serious gut infections often acquired in healthcare settings. Researchers found that after using the UV light in 87% of cleaning instances over a nine-month period, there was no decrease in CDI rates—meaning the infections remained the same before and after the UV light was used. This matters because it shows that this type of cleaning method did not improve patient safety by reducing these infections. Who this helps: This helps hospital administrators and infection control teams.

PubMed

Complications from "Stem Cell Tourism" in Neurology.

2020

Annals of neurology

Julian K, Yuhasz N, Rai W, Salerno JA, Imitola J

Plain English
Researchers studied the growing trend of "stem cell tourism," where patients seek unapproved stem cell treatments, particularly in neurology. They found that neurologists are often unprepared to discuss these therapies with patients and noted numerous unreported complications related to these procedures. Specifically, there is a clear need for better education for neurologists and for a national registry to track these complications. Who this helps: This helps patients seeking stem cell treatments.

PubMed

Retinal relaxation following membrane peeling: Effect on vision, central macular thickness, and vector analysis of motion.

2020

Journal of clinical and translational research

de Smet MD, Julian K, Maurin J, Jolissaint LP, Mura M

Plain English
This study looked at how removing epiretinal membranes (ERM) from the eye affects vision and the movement of blood vessels in the retina. Researchers found that while the improvement in vision was similar for eyes with more movement and those with less, the drop in central macular thickness — a key measure of retinal health — was most significant in those with greater displacement. Understanding how and where these changes occur after surgery can help doctors determine the best times to intervene and which sections of the membrane are most important for a successful outcome. Who this helps: This study benefits patients undergoing ERM surgery and their eye doctors.

PubMed

Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

2019

Clinical transplantation

Goldman JD, Julian K

Plain English
This study looked at how to diagnose, prevent, and manage urinary tract infections (UTIs) in kidney transplant patients, who have specific risks for these infections. The findings highlight that kidney transplant patients often face infections from antibiotic-resistant bacteria and that treating non-symptomatic bacteria in their urine doesn't help and may even do more harm if done after two months post-transplant. This matters because it helps doctors provide better care by avoiding unnecessary antibiotic use and targeting appropriate prevention strategies. Who this helps: This helps kidney transplant patients and their healthcare providers.

PubMed

Global effects of non-native tree species on multiple ecosystem services.

2019

Biological reviews of the Cambridge Philosophical Society

Castro-Díez P, Vaz AS, Silva JS, van Loo M, Alonso Á +33 more

Plain English
This study examined how non-native tree species (NNTs) affect various ecosystem services, such as providing timber, controlling erosion, and offering aesthetic value. Researchers analyzed 1,683 case studies from 44 countries and found that while NNTs generally improve services like soil fertility and climate regulation, they contribute less to timber supply compared to native trees. Understanding these impacts helps decision-makers manage and use NNTs sustainably, balancing benefits like increased soil health against drawbacks like reduced scientific interest. Who this helps: This research benefits environmental managers and policymakers who oversee forestry and ecosystem health.

PubMed

Convergence of human cellular models and genetics to study neural stem cell signaling to enhance central nervous system regeneration and repair.

2019

Seminars in cell & developmental biology

Julian D, Hollingsworth EW, Julian K, Imitola J

Plain English
This study looked at how insights from lower organisms can help us understand the behavior of neural stem cells (NSCs) in humans, which is crucial for repairing damage in the central nervous system. The researchers found that new methods, such as using patient-derived cells, can improve our understanding of how NSCs work and how they might be used to treat serious neurological conditions, while also highlighting risks like tumor formation. This research is important because better comprehension of NSC signaling could open pathways to new treatments for conditions like spinal cord injuries or neurodegenerative diseases. Who this helps: Patients with neurological diseases and their doctors.

PubMed

Journal peer review: a bar or bridge? An analysis of a paper's revision history and turnaround time, and the effect on citation.

2018

Scientometrics

Rigby J, Cox D, Julian K

Plain English
This study looked at how the peer review process for academic papers affects their future citations. Researchers found that papers with more revisions received greater recognition, with those revised multiple times being cited more often than others. This is important because it shows that peer review is not just about fixing mistakes; it actually plays a key role in improving the quality and impact of research. Who this helps: This helps researchers and academics aiming to improve their work's visibility and importance.

PubMed

The "Growing" Reality of the Neurological Complications of Global "Stem Cell Tourism".

2018

Seminars in neurology

Julian K, Yuhasz N, Hollingsworth E, Imitola J

Plain English
This study looked at the growing trend of "stem cell tourism," where patients seek unproven stem cell treatments for serious neurological conditions like multiple sclerosis and ALS. It found that this practice is increasing and can lead to significant neurological complications, endangering patients' health. The research emphasizes the need for better education and regulation to protect patients from these risky treatments and to maintain the integrity of legitimate stem cell research. Who this helps: This helps patients seeking treatment for neurological diseases and their families.

PubMed

The Health Professions Education Pathway: Preparing Students, Residents, and Fellows to Become Future Educators.

2017

Teaching and learning in medicine

Chen HC, Wamsley MA, Azzam A, Julian K, Irby DM +1 more

Plain English
This study looked at a program called the Health Professions Education Pathway at the University of California San Francisco, which helps medical students and health professionals become effective educators. From 2009 to 2014, 117 participants found that working within a community of educators helped them develop important teaching skills, confirm their career goals, and actively participate in educational projects. This matters because enhancing the quality of health education benefits future healthcare professionals, ultimately leading to better patient care. Who this helps: Patients and healthcare professionals who benefit from improved teaching and learning in health education.

PubMed

Faculty development efforts to promote screening, brief intervention, and referral to treatment (SBIRT) in an internal medicine faculty-resident practice.

2017

Substance abuse

Stone A, Wamsley M, O'Sullivan P, Satterfield J, Satre DD +1 more

Plain English
This study looked at how training programs for medical faculty could improve their ability to screen for and address substance misuse among patients using a method called SBIRT. After five years of training, 52% of faculty felt more confident in identifying substance use issues, and many reported screening more often, but they didn't feel that their teaching of this method to residents improved much. This matters because enhancing screening practices can lead to better identification and treatment of substance use disorders, which is crucial in primary care settings. Who this helps: Patients dealing with substance misuse issues.

PubMed

Multidrug and Mupirocin Resistance in Environmental Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Homes of People Diagnosed with Community-Onset MRSA Infection.

2017

Applied and environmental microbiology

Shahbazian JH, Hahn PD, Ludwig S, Ferguson J, Baron P +13 more

Plain English
This study looked at how the home environment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections is affected by the presence of drug-resistant MRSA strains. Researchers found that 68% of the homes had MRSA at the beginning of the study, which dropped to 51% after three months, but both times more than half of the samples were resistant to multiple drugs (61% at the start and 55% afterward). This is important because it shows that MRSA, especially multidrug-resistant types, is common in homes, potentially putting patients at risk of reinfection, and highlights a connection between the use of antibiotics in homes and the presence of these resistant strains. Who this helps: This helps patients recovering from MRSA infections and their families.

PubMed

An Intensive Continuity Clinic Immersion Experience for Interns: A Springboard to Confidence and Satisfaction With Continuity Clinic.

2017

Journal of graduate medical education

Dulay M, Laponis R, O'Brien BC, Gupta R, Ramanan RA +1 more

Plain English
This study looked at a special 3-week training program for new doctors, called interns, to help them gain confidence and satisfaction with their outpatient care skills. After completing this program, 124 interns showed a significant improvement in their confidence levels regarding medical knowledge and communication skills, with satisfaction ratings around 4.5 out of 5. This matters because better trained interns are likely to provide higher quality care to patients. Who this helps: This helps patients and their healthcare providers.

PubMed

Educating the Next Generation of Physicians in Interprofessional Collaboration.

2016

Journal of general internal medicine

Sheu L, Laponis R, Julian K

PubMed

Is Training in a Primary Care Internal Medicine Residency Associated with a Career in Primary Care Medicine?

2015

Journal of general internal medicine

Stanley M, O'Brien B, Julian K, Jain S, Cornett P +3 more

Plain English
This study looked at whether training in a primary care internal medicine residency leads to a career in primary care. It found that 54% of those who graduated from primary care residencies are now working mainly in outpatient primary care, compared to only 20% of those from categorical residencies. This matters because it demonstrates the important role residency training plays in shaping career paths, with many alumni losing interest in primary care during their training. Who this helps: This helps medical students and residency programs aiming to increase the number of primary care physicians.

PubMed

Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.

2014

Biological psychiatry

Smits JA, Rosenfield D, Davis ML, Julian K, Handelsman PR +6 more

Plain English
This research studied the effects of yohimbine, a supplement, on improving exposure therapy for adults with social anxiety disorder. In a trial with 40 participants, those who took yohimbine reported faster and better improvements in their anxiety levels compared to those who received a placebo, particularly if they reported low fear at the end of exposure tasks. The findings suggest that yohimbine might help enhance treatment for social anxiety, especially when combined with effective therapy sessions. Who this helps: This helps patients with social anxiety disorder looking for more effective treatment options.

PubMed

Frequent Co-Authors

James A Davis Danai Dima Rahul Banerjee Douglas W Sborov Doris K Hansen Jack Khouri Douglas Sborov Ghulam Rehman Mohyuddin Shebli Atrash Shahzad Raza

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.